

**Date: 12 December 2025**

To,  
Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
Mumbai-400 051

**Stock Code: NSE: SHILPAMED/BSE-530549**

Dear Madam/Sir,

**Sub: Shilpa Medicare Receives Initial Authorization for Rotigotine Transdermal Patch from Europe**

**Ref: Regulation 30 of the SEBI(LODR) Regulations**

This is to inform you that Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has received the Initial Authorization from Europe, recommending the grant of the final Marketing Authorization for Shilpa Medicare's prescription product, **Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch**.

This application, submitted as a generic application via Decentralized Procedure in Europe and is a generic version of the innovator product Neupro®. Shilpa's product is pharmaceutical and bioequivalent version of the reference product Neupro®. Shilpa's Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson's disease.

The total addressable European market for Rotigotine is estimated at ~USD 222 million. Shilpa has on boarded a strategic commercialization partner in Europe, with a targeted launch in FY27.

**This authorization represents a significant milestone for the Company, being Shilpa Medicare's First transdermal patch dosage form to receive marketing authorization in the European region.** The once-daily, patient-friendly transdermal formulation ensures reproducible, sustained, and controlled release of medication, enhancing patient compliance.

This approval has come from the Company's finished dosage form manufacturing facility, Shilpa Medicare Ltd, Unit VI, located at Dobbaspet, Bengaluru, Karnataka. This is the first approval of a prescription transdermal dosage Form in the European markets from this facility. The facility is involved in manufacturing, packaging, labelling and testing of specialized finished dosage forms as oral dispersible/dissolving Films and Transdermal Patches.

## ***Shilpa Medicare Limited***

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: [info@vbshilpa.com](mailto:info@vbshilpa.com), Web: [www.vbshilpa.com](http://www.vbshilpa.com)

CIN: L85110KA1987PLC008739

### **About Shilpa Medicare Limited**

**Shilpa Medicare Limited (BSE: 530549 | NSE: SHILPAMED)** is a leading Indian pharmaceutical company focused on the development, manufacture, and marketing of APIs, formulations, and biologics across oncology, infectious diseases, and specialty segments. With expertise in complex generics, novel drug delivery systems, and CDMO services, Shilpa serves patients in over 80 countries. For more information, visit [www.vbshilpa.com](http://www.vbshilpa.com)

Kindly take the same on record.

### **For Shilpa Medicare Limited**

**Ritu Tiwary**

**Company Secretary & Compliance Officer**